New Phase 3 Trial Data Confirm the Uniquely High Efficacy and Good Safety Profile of the R21/Matrix-M Malaria Vaccine in African Children
• Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5–17-month age group over the first year• To date 25 million doses manufactured and ready for roll-out by
Source: indiaeducationdiary.in
